BR0316004A - Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina - Google Patents

Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina

Info

Publication number
BR0316004A
BR0316004A BR0316004-1A BR0316004A BR0316004A BR 0316004 A BR0316004 A BR 0316004A BR 0316004 A BR0316004 A BR 0316004A BR 0316004 A BR0316004 A BR 0316004A
Authority
BR
Brazil
Prior art keywords
cdk
inhibitor
gemcitabine
pharmaceutical composition
relates
Prior art date
Application number
BR0316004-1A
Other languages
English (en)
Inventor
Athos Giannella-Borradori
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0225875.4A external-priority patent/GB0225875D0/en
Priority claimed from GB0300294A external-priority patent/GB0300294D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of BR0316004A publication Critical patent/BR0316004A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA COMPREENDENDO UM INIBIDOR DE CDK E GEMCITABINA". Um primeiro aspecto da invenção refere-se a uma combinação compreendendo um inibidor de CDK e gemcitabina. Um segundo aspecto da invenção refere-se a um produto farmacêutico compreendendo um inibidor de CDK e gemcitabina como uma preparação combinada para uso simuitâneo, seq³encial ou separado em terapia. Um terceiro aspecto da invenção refere-se a um método de tratamento de um distúrbio proliferativo, o dito método compreendendo administrar simultaneamente, seq³encialmente ou separadamente um inibidor de CDK e gemcitabina a um indivíduo.
BR0316004-1A 2002-11-06 2003-11-05 Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina BR0316004A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0225875.4A GB0225875D0 (en) 2002-11-06 2002-11-06 Combination
GB0300294A GB0300294D0 (en) 2003-01-07 2003-01-07 Combination
PCT/GB2003/004759 WO2004041308A1 (en) 2002-11-06 2003-11-05 Pharmaceutical composition comprising a cdk inhibitor and gemcitabine

Publications (1)

Publication Number Publication Date
BR0316004A true BR0316004A (pt) 2005-09-13

Family

ID=32313985

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316004-1A BR0316004A (pt) 2002-11-06 2003-11-05 Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina

Country Status (8)

Country Link
US (1) US20050267066A1 (pt)
EP (1) EP1558289A1 (pt)
JP (1) JP2006508184A (pt)
AU (1) AU2003276453A1 (pt)
BR (1) BR0316004A (pt)
CA (1) CA2502979A1 (pt)
MX (1) MXPA05004919A (pt)
WO (1) WO2004041308A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
ATE399766T1 (de) 2000-10-20 2008-07-15 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische heterozyklen
EP1558242B1 (en) * 2002-11-06 2008-12-24 Cyclacel Limited Combination comprising docetaxel and a cdk inhibitor
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
NZ563686A (en) * 2005-06-07 2011-07-29 Univ Yale Methods of treating cancer and other conditions or disease states using LFMAU and LDT
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
WO2007132220A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder
CN101443009A (zh) 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
US20090325931A1 (en) * 2006-07-28 2009-12-31 University Court Of The University Of Edinburgh Use of cdk inhibitors for the treatment of granulocyte mediated disorders
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
JPWO2008088088A1 (ja) 2007-01-19 2010-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 膵癌治療用組成物
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
CA2687204C (en) * 2007-05-15 2015-11-24 Piramal Life Sciences Limited A synergistic pharmaceutical combination for the treatment of cancer
EP2214662B1 (en) * 2007-10-22 2016-07-13 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
WO2010012777A1 (en) * 2008-07-29 2010-02-04 Nerviano Medical Sciences S.R.L. THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
EP2874631A1 (en) 2012-05-15 2015-05-27 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
JPWO2014010742A1 (ja) * 2012-07-13 2016-06-23 学校法人神戸学院 モノガラクトシルジアシルグリセロール又はその薬学的に許容し得る塩を有効成分として含む医薬組成物又は食品組成物
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
AR096892A1 (es) 2013-07-12 2016-02-03 Piramal Entpr Ltd Una combinación farmacéutica para el tratamiento del melanoma
EP3825305A1 (en) 2014-08-28 2021-05-26 Eisai R&D Management Co., Ltd. Process for preparing lenvatinib
PT3263106T (pt) 2015-02-25 2024-01-12 Eisai R&D Man Co Ltd Método para suprimir o amargor do derivado de quinolina
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
KR20180018695A (ko) 2015-06-16 2018-02-21 가부시키가이샤 프리즘 파마 항암제
CN113559058A (zh) * 2021-07-30 2021-10-29 石家庄学院 吉西他滨氨基酸注射液

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531477B1 (en) * 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
CA2420164A1 (en) * 2000-10-20 2002-05-02 Bristol-Myers Squibb Pharma Company Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors
AU2002228692A1 (en) * 2000-12-01 2002-06-11 Bristol-Myers Squibb Pharma Company 3-(2,4-dimethylthiazol-5-yl) indeno(1,2-c)pyrazol-4-one derivatives as cdk inhibitors
CA2430376A1 (en) * 2000-12-08 2002-06-13 David J. Carini Semicarbazides and their uses as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
US20050267066A1 (en) 2005-12-01
WO2004041308A1 (en) 2004-05-21
EP1558289A1 (en) 2005-08-03
CA2502979A1 (en) 2004-05-21
JP2006508184A (ja) 2006-03-09
AU2003276453A1 (en) 2004-06-07
MXPA05004919A (es) 2005-08-18

Similar Documents

Publication Publication Date Title
BR0316004A (pt) Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
BRPI0509927A (pt) composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
BRPI0517481A (pt) método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
TW200612987A (en) Combination treatment for non-hematologic malignancies
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
BRPI0418029A (pt) formulação de anticorpos cd40 e métodos
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
BRPI0616982B8 (pt) uso de oligouronato, composição farmacêutica inalável e aplicador de spray
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
BRPI0810336A2 (pt) "método para tratar e/ou prevenir úlceras de pele em um indivíduo"
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
BRPI0510760A (pt) método para administrar a um paciente uma composição, composição tópica, e, emplastro
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
PT1711185E (pt) Combina??o de roscovitina cs-682 ou seu metabolito cndac
AR004326A1 (es) Utilizacion de al menos un antagonista de tnf-alfa, composicion cosmetica, farmaceutica o dermatologica que contiene dicho antagonista y procedimiento detratamiento cosmetico empleando dicho antagonista.
ATE361065T1 (de) Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]